New drug GT801 tested for tough autoimmune cases

NCT ID NCT07333118

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called GT801 in 22 people with moderate-to-severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GT801 injection (a biological drug)

What this could lead to

If it works, this could point toward a new treatment option for people with hard-to-treat autoimmune diseases like lupus.

What could go wrong

This is a very early, small trial (22 people) focused mainly on safety. The treatment may not work or could have side effects. Much more research is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease idiopathic inflammatory myopathy systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Changzheng Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact